Maxim Group analyst Jason McCarthy maintained a Buy rating on Adamis Pharma (ADMP) today and set a price target of $10. The company’s shares opened today at $2.33, close to its 52-week low of $2.01.
McCarthy observed:
“On 3/15, Adamis reported YE18 results with $15.1M in revenue (compounding business) and a net loss of ($39.4M), ending the period with $19.3M in cash.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.3% and a 36.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adamis Pharma with a $6.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.10 and a one-year low of $2.01. Currently, Adamis Pharma has an average volume of 426.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets.
